Cancer

1. SU L, Burcu M, Ports K, Gradinariu V, et al
   Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials.
   Cancer. 2026;132:e70630.
   

   >> Share

   
   

   
   Cancer Res

2. LI N, Lavudi K, Ge Q, Yang Y, et al
   Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer to PARP Inhibitors.
   Cancer Res. 2026 Sep 28. doi: 10.1158/0008-5472.CAN-26-1379.
   

   >> Share

   
   
3. CHENG K, Nie H, Zhou W, Guo D, et al
   Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance.
   Cancer Res. 2026;86:4934-4954.
   

   >> Share

   
   

   
   Gynecol Oncol

4. SMITH G, Petty A, Krivanek K, Rose PG, et al
   Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer.
   Gynecol Oncol. 2026;214:22-26.
   

   >> Share

   
   

   
   Int J Cancer

5. WANG T, Zhao D, Song Y, Wu Y, et al
   BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes.
   Int J Cancer. 2026 Oct 1. doi: 10.1002/ijc.70759.
   

   >> Share

   
   

   
   Oncogene

6. THIRUSANGU P, Ray U, Jin L, Das B, et al
   Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in ovarian cancer.
   Oncogene. 2026 Oct 1. doi: 10.1038/s41388-026-04001.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share